Behind the Seizure®: No-cost epilepsy gene panel testing program
Behind the Seizure® is an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy, established by BioMarin and Invitae. With financial support from Praxis and other participating companies, Behind the Seizure will allow healthcare providers to order no-cost genetic testing for any child under the age of 8 who has had an unprovoked seizure.
An epilepsy gene panel can bring you closer to understanding what is causing your patient’s epilepsy, helping your patients and their caregivers benefit from deeper knowledge and timely care.
- More than 50% of epilepsies have some genetic basis. When a patient presents with seizures, genetic testing may help identify 100+ underlying genetic causes. Early genetic testing may be the most direct, cost-effective, and accurate diagnostic tool.1
- Many genes are actionable. Gene panels increasingly help tailor the approach—and identifying a seizure’s underlying etiology may enable more precise disease management.
- Delay can be devastating for patients with genetic epilepsy. Some genetic epilepsies are neurodegenerative, and may initially present with subtle, non-specific symptoms like language development delay and/or motor disturbance. Genetic testing may help identify the cause of epilepsy before a patient experiences the hallmark signs of regression.
- Genetic epilepsies may be hiding behind non-specific symptoms. Language delay, motor disturbance, and intellectual impairment are often comorbidities and useful indicators for molecular genetic testing.2
Some participants in the Behind the Seizure program are diagnosed 1 to 2 years earlier than reported averages. Healthcare professionals must confirm that patients meet certain criteria to use the program. All testing and services are performed by Invitae.
While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing is available in the US and Canada. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any other products or services from Invitae or from third parties or commercial organizations.